



Mitochondrial-dependent apoptosis in Huntington's disease human cybrids

Ildete L. Ferreira^a, Maria V. Nascimento^a, Márcio Ribeiro^a, Sandra Almeida^a, Sandra M. Cardoso^a,
Manuela Grazina^{a,b}, João Pratas^a, Maria João Santos^a, Cristina Januário^c,
Catarina R. Oliveira^{a,b}, A. Cristina Rego^{a,b,*}

^a Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Portugal

^b Institute of Biochemistry, Faculty of Medicine, University of Coimbra, Portugal

^c Neurology Unit, Coimbra University Hospital, Coimbra, Portugal

ARTICLE INFO

Article history:

Received 10 September 2009

Revised 26 November 2009

Accepted 5 January 2010

Available online xxx

Keywords:

Apoptosis

Human cybrids

Huntington's disease

Mitochondria

3-Nitropropionic acid

ABSTRACT

We investigated the involvement of mitochondrial-dependent apoptosis in Huntington's disease (HD) vs. control (CTR) cybrids, obtained from the fusion of human platelets with mitochondrial DNA-depleted NT2 cells, and further exposed to 3-nitropropionic acid (3-NP) or staurosporine (STS). Untreated HD cybrids did not exhibit significant modifications in the activity of mitochondrial respiratory chain complexes I–IV or in mtDNA sequence variations suggestive of a primary role in mitochondrial susceptibility in the subpopulation of HD carriers studied. However, a slight decrease in mitochondrial membrane potential and increased formation of intracellular hydroperoxides was observed in HD cybrids under basal conditions. Furthermore, apoptotic nuclei morphology and a moderate increase in caspase-3 activation, as well as increased levels of superoxide ions and hydroperoxides were observed in HD cybrids upon 3-NP or STS treatment. 3-NP-evoked apoptosis in HD cybrids involved cytochrome c and AIF release from mitochondria, which was associated with mitochondrial Bax translocation. CTR cybrids subjected to 3-NP showed increased mitochondrial Bax and Bim levels and the release of AIF, but not cytochrome c, suggesting a different mode of cell death, linked to the loss of membrane integrity. Additionally, increased mitochondrial Bim and Bak levels, and a slight release of cytochrome c in untreated HD cybrids may help to explain their moderate susceptibility to mitochondrial-dependent apoptosis.

© 2010 Published by Elsevier Inc.

Introduction

Huntington's disease (HD) is an autosomal dominant disorder characterized by uncontrolled body movements known as chorea, changes in personality and a loss of cognitive ability eventually leading to dementia. HD is caused by an expansion of the trinucleotide CAG repeat in the huntingtin gene, producing a protein with increased number of polyglutamines at the N-terminal (mutant huntingtin). Neuropathological changes are caused by the death of GABAergic projection medium-spiny neurons of the neostriatum (caudate and putamen) and neurons in the cerebral cortex, the two most severely affected brain structures in HD (e.g., Gil and Rego, 2008). However, the mechanisms by which mutant huntingtin causes selective degeneration of striatal and cortical neurons in HD are largely unknown.

Neuronal abnormalities involving aberrant protein–protein interactions caused by mutant huntingtin may lead to deregulation in gene

expression in human HD striatum (Kuhn et al., 2007). Furthermore, excitotoxicity linked to decreased Ca²⁺ homeostasis, mitochondrial dysfunction, impairment in energy metabolism (Schapira, 1998; Beal, 2005; Sas et al., 2007; Sorolla et al., 2008; Yang et al., 2008), caspase activation and apoptosis (Brouillet et al., 1998; Beal, 2005; Milakovic and Johnson, 2005; Rego and de Almeida, 2005; Fan and Raymond, 2007) have been reported in HD-affected individuals. In addition, oxidative stress and damage to specific macromolecules also participate in HD progression (Sorolla et al., 2008).

Analysis of post-mortem striatal tissue from HD patients revealed a decrease in the activity of the respiratory chain complexes II/III and IV (Schapira 1998; Tabrizi et al., 1999). Mutant huntingtin may cause mitochondrial dysfunction by either perturbing transcription of nuclear-encoded mitochondrial proteins or by directly interacting with the organelle, thus evoking defects in mitochondrial dynamics, organelle trafficking and fission and fusion, which, in turn, may result in bioenergetic failure in HD (Bossy-Wetzel et al., 2008). Indeed, mild or gradual energy disturbances may lead to the release of pro-apoptotic factors from the mitochondria, such as cytochrome c, leading to apoptotic cell death. However, if the energy supply of the cell drops dramatically, cells die by necrosis (Vanlangenakker et al., 2008).

* Corresponding author. Center for Neuroscience and Cell Biology, and Institute of Biochemistry, Faculty of Medicine, Ruas Larga, University of Coimbra, 3004-504 Coimbra, Portugal. Fax: +351 239 822776.

E-mail addresses: a.cristina.rego@gmail.com, acrego@cnc.cj.uc.pt (A.C. Rego).

Mutant huntingtin is widely expressed in the HD brain (Aronin et al., 1995; Trotter et al., 1995), but also in peripheral tissues. Thus, abnormalities outside the brain can also be expected. Accordingly, mutant huntingtin was reported to be associated with mitochondrial complex II/III dysfunction, mitochondrial depolarization, cytochrome c release and increased caspases activity in skeletal muscle (Ciammola et al., 2006; Turner et al., 2007), and decreased catalase activity in skin fibroblast cultures from HD patients (del Hoyo et al., 2006). Lymphoblasts derived from HD patients also show increased stress-induced apoptotic cell death associated with caspase-3 activation, abnormal calcium homeostasis and mitochondrial dysfunction (Sawa et al., 1999; Panov et al., 2002; Bezprozvanny and Hayden, 2004). Recently, we demonstrated that HD human peripheral blood cells, particularly B lymphocytes, are endowed with increased expression of Bax and decreased mitochondrial membrane potential (Almeida et al., 2008), further suggesting that an adverse effect of mutant huntingtin is not limited to neurons.

It is widely accepted that mitochondrial DNA (mtDNA) abnormalities play an important role in neurodegenerative diseases (Grazina et al., 2006; Onyango et al., 2006), even if they are not a primary triggering factor (Mancuso et al., 2008). mtDNA mutations may modify the age of onset, as a result of an impairment of mitochondrial respiratory chain and/or translational mechanisms thus contributing to the neurodegenerative process (Grazina et al., 2006). Even though the studies concerning HD and mtDNA mutations are rare and heterogeneous, mtDNA mutations have been suggested to occur in HD pathophysiology (Kasraie et al., 2008; Yang et al., 2008). It was recently demonstrated that mitochondrial DNA damage is an early biomarker for HD-associated neurodegeneration supporting the hypothesis that mtDNA lesions may contribute to the pathogenesis observed in HD (Acevedo-Torres et al., 2009). Indeed, recent data showed that HD patients' lymphocytes have higher frequencies of mtDNA deletions and oxidative stress, suggesting that CAG repeats instability and mutant huntingtin are a causative factor in mtDNA damage (Banoei et al., 2007). Nevertheless, previous studies in HD cybrids (a valuable cellular tool to isolate mitochondrial-encoded human defects) showed no changes in mitochondrial respiratory chain activity or oxidative stress (Swerdlow et al., 1999), evidencing no major changes in mitochondrial function, even if considering the occurrence of point mtDNA mutations. Notwithstanding, mutant huntingtin was previously shown to interact with neuronal mitochondria of YAC72 transgenic mice suggesting that mitochondrial calcium abnormalities associated with HD pathogenesis may be due to a direct effect of mutant huntingtin on the organelle (Panov et al., 2002). Moreover, mutant huntingtin fragments can directly induce the opening of the mitochondrial permeability transition pore in isolated mouse liver mitochondria, with the consequent release of cytochrome c (Choo et al., 2004), favoring the hypothesis that mutant huntingtin interacting with mitochondria may well lead to mitochondrial modifications independently of damage on mtDNA.

Thus, in the present study, we studied mitochondrial-dependent apoptotic events and oxidative stress in human cybrid lines, obtained from the fusion of HD or control platelets with NT2 ρ^0 cells, depleted of mitochondrial DNA. We report increased susceptibility of a subpopulation of HD cybrids, an *ex vivo* mitochondrial HD human model, to undergo mitochondrial-dependent apoptosis when subjected to complex II inhibition with 3-nitropropionic acid (3-NP) or to apoptosis with the classic inducer staurosporine (STS).

Materials and methods

Materials

Optimem was purchased from GIBCO (Paisley, UK). Protease inhibitor cocktail (chymostatin, pepstatin, A, leupeptin and antipain), 3-nitropropionic acid, penicillin/streptomycin, oligomycin, carbonyl-

cyanide-*p*-(trifluoromethoxyphenyl)hydrazine (FCCP), dichlorophenolindophenol (DCPIP), thenoyltrifluoroacetone (TTFA), 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB) and anti- α -tubulin were from Sigma Chemical Co. (St Louis, MO, USA). *N*-acetyl-Asp-Glu-Val-Asp-*p*-nitroanilide (Ac-DEVD-pNA) was obtained from Calbiochem (Darmstadt, Germany). Anti-cytochrome c was from BD Pharmingen (San Diego, CA, USA); anti-Bax from Cell Signaling (Beverly, MA, USA); anti-Bcl-2 and anti-AIF from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-Bim from Stressgen (Assay Designs, Inc., Michigan, USA); and anti-Bak from Abcam Inc. (Cambridge, USA). Secondary antibodies conjugated to alkaline phosphatase (anti-mouse and anti-rabbit) were purchased from Amersham Biosciences (Buckinghamshire, UK). The fluorescence probes tetramethylrhodamine methyl ester (TMRM+), dihydroethidium (DHE), 2',7'-dichlorodihydrofluorescein diacetate (DCFH₂-DA), Hoechst 33342 and anti-cytochrome c oxidase I (COX I) were obtained from Molecular Probes (Invitrogen, USA). All other reagents were of analytical grade.

Participants

Five to six genetically and clinically confirmed HD patients from pre-identified Portuguese families and three age-matched healthy controls, without any neurological disease, were studied. The number of CAG repeats present in HD gene for all the patients were between 42 and 44, which gives rise to the most common adult-onset form of the disease. The patients were characterized according to the Unified Huntington's Disease Rating Scale (UHDRS) (Huntington Study Group, 1996) and neurological evaluation was performed by an experienced neurologist. The study was performed in accordance with the Ethical Committee of Coimbra University Hospital, and all the subjects gave informed consent.

Cybrid production, culture and incubation with 3-NP and STS

Cybrids (cytoplasmic hybrid systems) were produced after fusion of mitochondrial DNA-depleted human teratocarcinoma cells (ρ^0 NT2 cells), obtained from Dr. R. H. Swerdlow (University of Virginia, Charlottesville, VA, USA), with human platelets. Production and selection of the cybrids were performed as described previously (Cardoso et al., 2004). Cybrids were cultured in Optimem medium supplemented with 10% of fetal calf serum, penicillin (100 U/ml), streptomycin (100 μ g/ml) and maintained at 37 °C in humidified incubator containing 95% air and 5% CO₂. Since mitochondria divide mainly in response to the energy needs of the cell, i.e., independently of the cell cycle (Sas et al., 2007) and to account for the auto-selection of the remaining functional mitochondria, experiments were performed with cybrids less than 2 months in culture, as previously described (e.g., Cardoso et al., 2004). Cybrids were plated on glass coverslips, multiwell chambers or flasks at a density of 0.06×10^6 cells/cm² one day before the experiments in order to allow the desired confluence. Cells were then incubated in culture medium in the absence or presence of 3-NP (0.1, 1 or 10 mM) for 24 h or STS (0.1, 1 or 10 nM) for 15 h, as described in figure legends.

Assay of enzymatic activities of mitochondrial electron transport chain

Cybrids were extracted in a sucrose buffer (250 mM sucrose; 20 mM HEPES-KOH, pH 7.5; 100 mM KCl; 1.5 mM MgCl₂; 1 mM EDTA and 1 mM EGTA), and centrifuged at 2300 rpm for 12 min at 4 °C. The supernatant was analyzed for mitochondrial complex activities on a UV/VIS spectrophotometer (model 2401; Shimadzu Scientific Instruments, Columbia, MD).

NADH-ubiquinone oxidoreductase assay

Complex I activity was determined at 340 nm by following the decrease in NADH absorbance that occurs when ubiquinone is

- 204 reduced to ubiquinol. The reaction was started by adding the sample
205 to the reaction mixture (in mM: 20 K₂HPO₄, pH 7.2, 10 MgCl₂, 0.15
206 NADH, 2.5 mg/ml BSA fatty-acid free, 1 KCN) containing 50 μM
207 decylubiquinone, at 30 °C. After 8 min, rotenone (10 μM) was added
208 and the reaction was registered for further 8 min. Complex I activity
209 was expressed in nanomoles per minute per milligram of protein and
210 correspond to the rotenone sensitive rate. The enzyme activity was
211 corrected for citrate synthase activity.
- 212 *Succinate–ubiquinone oxidoreductase assay*
213 Complex II activity was monitored at 600 nm by following the
214 reduction of 6,6-dichlorophenolindophenol (DCPIP) by the ubiquinol
215 formed in the reaction. The assay was started by adding the sample to
216 the reaction mixture (in mM: 50 K₂HPO₄, pH 7.4, 20 succinate, 0.1
217 EDTA, 1 KCN, 0.01 rotenone) containing 50 μM decylubiquinone, at
218 30 °C. After 8 min, 1 mM 2-thenoyltrifluoroacetone (TTFA) was added
219 and the reaction registered for further 8 min. Complex II activity was
220 expressed in nanomoles per minute per milligram of protein and
221 correspond to the TTFA sensitive rate. The enzyme activity was
222 corrected for citrate synthase activity.
- 223 *Ubiquinol–cytochrome c reductase assay*
224 Complex III activity was monitored at 550 nm by following the
225 reduction of cytochrome c by ubiquinol. The assay was started by
226 adding the sample to the reaction mixture (in mM: 35 K₂HPO₄, pH 7.2,
227 1 EDTA, 5 MgCl₂, 1 KCN, 5 μM rotenone) containing 15 μM cytochrome
228 c and 15 μM ubiquinol, at 30 °C. Complex III activity was expressed in
229 rate constant (k) per minute per milligram of protein and corrected
230 for citrate synthase activity.
- 231 *Cytochrome c oxidase assay*
232 Complex IV activity was determined at 550 nm by measuring the
233 oxidation of reduced cytochrome c by cytochrome c oxidase. The
234 reduced cytochrome c was prepared by mixing its oxidized form with
235 ascorbate and then dialysed for 24 h against a 0.01 M phosphate
236 buffer, pH 7.0, at 4 °C. The assay was started by adding the sample to
237 the reaction buffer (10 mM K₂HPO₄, pH 7) containing 50 μM reduced
238 cytochrome c and 1 mM ferricyanide, at 30 °C. Complex IV activity was
239 expressed in rate constant (k) per minute per milligram of protein and
240 corrected for citrate synthase activity.
- 241 *Citrate synthase assay*
242 Citrate synthase (CS) activity was performed at 412 nm following
243 the reduction of 0.2 mM 5,5'-dithio-bis(2-nitrobenzoic acid) in the
244 presence of 0.2 mM acetyl-CoA and 0.1 mM oxaloacetate in a medium
245 with 100 mM Tris-HCl, pH 8.0 and 0.1% Triton X-100. CS activity was
246 expressed in nanomoles per minute per milligram of protein.
- 247 *Analysis of mitochondrial membrane potential*
248 The mitochondria membrane potential was determined by using
249 the cationic fluorescent probe tetramethyl rhodamine methyl ester
250 (TMRM⁺), which accumulates predominantly in polarized mitochondria
251 (Ward et al., 2000). Thus the variation of TMRM⁺ retention was
252 studied in order to estimate changes in mitochondrial membrane
253 potential. Following a washing step with Na⁺ medium containing (in
254 mM): 135 NaCl, 5 KCl, 0.4 KH₂PO₄, 1.8 CaCl₂, 1 MgSO₄, 20 HEPES, and
255 5.5 glucose, pH 7.4, cells were incubated in Na⁺ medium containing
256 150 nM TMRM⁺ (quench mode) for 1 h at 37 °C. Basal fluorescence
257 (540 nm excitation and 590 emission) was measured using a
258 Microplate Spectrofluorometer Gemini EM (Molecular Devices, USA)
259 for 5 min, followed by the addition of 1 μM FCCP and 2 μg/ml
260 oligomycin, which produced maximal mitochondrial depolarization.
261 Results were expressed as the difference between the increase of
262 TMRM⁺ fluorescence upon addition of FCCP plus oligomycin and basal
263 fluorescence values.
- Analysis of apoptotic nuclei*
264
265 The nuclear morphology of HD and CTR cybrids exposed to 3-NP
266 or STS was analyzed by fluorescence microscopy, by using a double-
267 staining procedure with Hoechst 33342 and propidium iodide.
268 Following a washing step with Na⁺ medium, the cells were
269 incubated with 7.5 μg/ml Hoechst 33342 and 4 μg/ml propidium
270 iodide, in the dark, for 3 min, at room temperature. Cells were
271 washed 3 times in Na⁺ medium in order to remove extracellular
272 dyes and further examined and scored using the Axioscope 2 Plus
273 upright microscope (Zeiss, Jena, Germany).
- Lactate dehydrogenase (LDH) measurements*
274
275 The integrity of the plasma membrane was determined by
276 monitoring the activity of the cytoplasmic enzyme LDH in the
277 extracellular incubation medium, which represents a common proce-
278 dure to determine membrane leakage and necrotic cell damage. After
279 exposure to 3-NP or STS, the incubation medium was collected
280 (extracellular) and the cells were lysed in 10 mM HEPES (pH 7.4) plus
281 0.01% Triton X-100 (intracellular) and frozen at –80 °C. Cell debris in
282 both samples were removed by centrifugation at 14,000 rpm (Eppendorf
283 Centrifuge 5417R), for 10 min. LDH was determined spectrophotomet-
284 rically, by following the rate of conversion of reduced nicotinamide
285 adenine dinucleotide (NADH) to oxidized NAD⁺ at 340 nm (Bergmeyer
286 and Bernt, 1974). LDH released into the extracellular medium was
287 expressed as a percentage of the total LDH activity in the cells [% of LDH
288 released = extracellular LDH/(extracellular LDH + intracellular LDH)].
- Analysis of intracellular superoxide ions*
289
290 The cybrids were incubated for 60 min at 37 °C in the presence of 5 μM
291 DHE, in Na⁺ medium. DHE is a cell-permeable fluorescent dye that, once
292 internalized, is oxidized by superoxide to fluorescent ethidium bromide,
293 which intercalates into DNA. DHE itself shows a blue fluorescence
294 (355 nm excitation, 420 nm emission) in cell cytoplasm until oxidation to
295 form ethidium, which becomes red fluorescent (518 nm excitation,
296 605 nm emission) upon DNA intercalation. Ethidium bromide fluores-
297 cence intensity was measured continuously for 1 h at 37 °C, and the
298 relative level of superoxide production quantified, using a Microplate
299 Spectrofluorometer Gemini EM (Molecular Devices, USA). At the end of
300 each experiment, the cells were scrapped to quantify cell protein in each
301 well, using the BioRad protein assay, and ethidium fluorescence was
302 corrected for variations in total protein between wells. The values were
303 normalized to the percentage of control (untreated cybrids).
- Intracellular hydroperoxides analysis*
304
305 Cybrids were incubated for 30 min in the presence of 20 μM
306 DCFH₂-DA, a stable non-fluorescent cell permeable compound, at
307 37 °C in Na⁺ medium, pH 7.4. When internalized by the cell, DCFH₂-
308 DA is hydrolyzed to DCFH₂ by intracellular esterases and rapidly
309 oxidized to the highly green fluorescent component 2,7-dichloro-
310 fluorescein (DCF) by endogenous hydroperoxides. Intracellular levels
311 of peroxides were measured by following DCF fluorescence (480 nm
312 excitation, 550 nm emission) at 37 °C continuously for 1 h, using a
313 microplate reader Spectrofluorometer Gemini EM (Molecular Devices,
314 USA). In order to correct the DCF fluorescence values for variations in
315 total protein content in the wells, cell protein in each well was
316 quantified by the BioRad protein assay. The values were normalized to
317 the percentage of the control (untreated cybrids).
- Caspase-3 activity assay*
318
319 After washing, cells were scrapped at 4 °C in lysis buffer containing
320 25 mM HEPES, 2 mM MgCl₂, 1 mM EDTA and 1 mM EGTA, pH 7.5,

321 supplemented with 2 mM DTT, 0.1 mM phenylmethylsulphonyl
 322 fluoride (PMSF) and 1:1000 of protease inhibitor cocktail (chymos-
 323 tatin, pepstatin A, leupeptin and antipain). Cells were frozen two
 324 times in liquid N₂ and centrifuged at 14,000 rpm for 10 min
 325 (Eppendorf Centrifuge 5417R). The resulting supernatants were
 326 assayed for protein content by the BioRad protein assay. To measure
 327 caspase-3 activity, 30 µg protein were added to a reaction buffer
 328 [25 mM HEPES, 10% (m/v) sucrose, 0.1% (m/v) 3-[(3-cholamidopropyl)
 329 dimethylammonio]-1-propane-sulfonate CHAPS), pH 7.5] contain-
 330 ing the colorimetric substrate (100 µM) for caspase-3 (Ac-DEVD-
 331 pNA)-like activity. The reaction mixture was incubated at 37 °C for 2 h,
 332 and the formation of pNA was measured at 405 nm using a microplate
 333 reader Spectra Max Plus 384 (Molecular Devices, USA). Caspase-like
 334 activity was calculated as the increase above control for equal amount
 335 of loaded protein.

Western blot analysis in mitochondrial and cytosolic subcellular fractions 336

337 After a washing step, cybrids were scrapped at 4 °C in sucrose
 338 buffer containing 250 mM sucrose, 20 mM HEPES, 100 mM KCl,
 339 1.5 mM MgCl₂, 1 mM EDTA and 1 mM EGTA, pH7.5/KOH,
 340 supplemented with 1 mM DTT, 1 mM PMSF and 1:1000 protease
 341 cocktail inhibitor (chymostatin, pepstatin A, leupeptin and antipain).
 342 Cellular extracts were homogenized (20 strokes) and centrifuged at
 343 500×g for 12 min to pellet the nucleus and cell debris. The
 344 supernatant was further centrifuged at 12,000×g for 20 min and
 345 the resulting pellet (mitochondrial fraction) was resuspended in
 346 supplemented TNC buffer containing 10 mM Tris acetate pH 8, 0.5%
 347 Nonidet P40, 5 mM CaCl₂ supplemented with 1:1000 of protease
 348 cocktail inhibitor. TCA 15% was added to the supernatant and
 349 centrifuged at 15,000×g for 10 min. The resulting pellet (cytosolic




Fig. 1. Mitochondrial specific activities of complexes I–IV and mitochondrial membrane potential in HD and CTR cybrids. Mitochondrial complex enzymatic activities (A–D) normalized for the activity of citrate synthase (E) and mitochondrial membrane potential (F) were determined as described in *Materials and methods*. No significant differences were observed in the respiratory complexes activities. Data are the mean \pm S.E.M. of 6–8 independent experiments performed in duplicates. Statistical analysis was performed by two-way ANOVA, followed by Bonferroni post test. * $p < 0.05$, ** $p < 0.01$ when compared to CTR cybrids; ### $p < 0.001$ when compared to control (untreated) conditions.

350 fraction) was resuspended in supplemented sucrose buffer and
 351 adjusted to pH 7 with 2.5 M KOH. Protein content was determined
 352 by BioRad method, and the samples were denaturated with 6 times
 353 concentrated denaturing buffer at 95 °C, for 5 min. Equivalent
 354 amounts of protein were separated on a 15% SDS-PAGE gel
 355 electrophoresis and electroblotted onto polyvinylidene difluoride
 356 (PVDF) membranes. The membranes were further blocked with 5%
 357 fat-free milk and incubated with antibodies directed against the
 358 denatured form of cytochrome c (Cyt c, 1:500), AIF (1:1000), Bax
 359 (1:1000), Bim (1:1000), Bak (1:5000), Bcl-2 (1:500), α -tubulin
 360 (1:20000) and mitochondrial DNA-encoded cytochrome c oxidase
 361 subunit I (COX-I, 1:500). In some membranes retaining mitochondrial
 362 samples where labeling with COX-I was not possible, we used the
 363 antibody directed against α -tubulin (1:20000) to normalize the
 364 amount of protein per lane. Tubulin is an inherent component of
 365 mitochondrial membranes (Carré et al., 2002) and its levels did not
 366 change in any of the treatments used in this study. Immunoreactive
 367 bands were visualized by alkaline phosphatase activity after incuba-
 368 tion with ECF reagent on a BioRad Versa Doc 3000 Imaging System.

369 Mitochondrial DNA (mtDNA) screening

370 Total DNA was extracted from 5 HD and 3 CTR cybrids by using
 Q1 371 standard methods (Treco et al., 1992) and quantified by UV
 372 spectrophotometry ($\lambda=260$ nm). Automated sequencing analysis
 373 were used, according to the manufacturer's instructions (3130 ABI
 374 Prism sequencing system), using BigDye® Terminator Ready Reaction
 375 Mix v1.1 (Applied Biosystems), for investigation of 11 mtDNA regions
 376 corresponding to nucleotides 1435–1917, 3150–3769, 4074–4703,
 377 4886–5021, 7241–7644, 8222–8461, 8915–9413, 11720–11819, 13515–
 378 13727, 14420–14855, 15023–15450, allowing the screening of 31
 379 confirmed pathogenic mutations, 105 reported mutations and 288
 380 polymorphisms, including 4 haplogroup markers, according to
 381 MITOMAP (www.mitomap.org). Evolutionary conservation analysis
 382 among species for positions with novel variants identified was
 383 achieved using ENSEMBL® tools.

384 Statistical analysis

385 No significant differences in biochemical studies were observed
 386 between the HD cybrid lines and the three CTR cybrids used in this
 387 work. Therefore data were expressed as the mean \pm S.E.M. of the
 388 number of experiments indicated in the figure legends. Comparisons
 389 between multiple groups were performed with a two-way analysis of
 390 variance (ANOVA), followed by Bonferroni post-test for comparison
 391 between experimental groups. Student's *t* test was also performed for
 392 comparison between two Gaussian populations, as described in figure
 393 legends. Significance was accepted at $p<0.05$.

394 Results

395 Mitochondrial electron transport chain activities and mitochondrial 396 membrane potential

397 We measured the activity of mitochondrial respiratory chain
 398 complexes and the mitochondrial membrane potential in HD and CTR
 399 cybrids. Our data show no significant changes in the activities of
 400 respiratory complexes I, II, III and IV (Figs. 1A–D) or citrate synthase
 401 (Fig. 1E) in HD vs. CTR cybrids. Although the putative basal leak
 402 current and the coupling between oxygen consumption and ATP
 403 synthesis may be underestimated by assaying the catalytic activities
 404 of mitochondrial complexes, the latter measurement is important to
 405 evaluate putative changes between our HD cybrids and the data
 406 generated by Swerdlow et al. (1999).

407 We determined TMRM⁺ mitochondrial accumulation after com-
 408 plete mitochondrial depolarization due to the addition of FCCP plus

oligomycin, which gave rise to a measurable “spike” of cell
 fluorescence as a result of TMRM⁺ dequenching. We observed a
 slight, but significant, decrease in TMRM⁺ release from mitochondria,
 suggestive of decreased mitochondrial membrane potential in
 untreated HD cybrids (Fig. 1F). The 3-NP evoked decrease in TMRM⁺
 release was similarly exacerbated (50% decrease, $p<0.001$) upon
 exposure of both HD and CTR cybrids to 10 mM 3-NP, but not 1 mM 3-
 NP (Fig. 1F).

Mitochondrial DNA (mtDNA) screening

417 Despite the lack of differences in mitochondrial complexes
 418 activities, both HD and CTR cybrids were subjected for mtDNA
 419 screening. Results depicted in Table 1 summarize mtDNA findings in
 420 cybrids derived from HD patients and CTR subjects. The results were
 421 heterogeneous, revealing different patterns of mtDNA variations, both
 422 in controls and HD patients and sequence variations were found in 3
 423 (60%) out of 5 patients. One pathogenic mutation, 3394A > G, with
 424 status “unclear,” according to MITOMAP (www.mitomap.org) was
 425 found in one (HD-5) of 5 patients (20%) with 38-year-olds and 25/44
 426 CAG repeats genotype, together with other polymorphic variants.
 427 Furthermore, we found 3 novel sequence variations in the control
 428 subjects, occurring in genetic regions that are phylogenetically
 429 moderate or highly conserved.
 430

Effect of 3-NP and STS on cell viability

431 In order to evaluate the susceptibility of HD vs. CTR cybrids, we
 432 studied the effect of 3-NP and STS on nuclei morphology and LDH
 433 release. The cybrids were incubated with 1 and 10 mM 3-NP (Figs. 2A,
 434

Table 1
 Summary of mtDNA investigation in HD and control cybrids.

Sample	mtDNA sequence variations	Status (according to MITOMAP)	Gene		
HD-1	None			t1.4	
HD-2	None			t1.5	
HD-3	3348A>G	CRP	MTND1	t1.6	
	11719G>A	CRP UnP in oral cancer	MTND4	t1.7	
HD-4	14766C>T	CRP	MTCYB	t1.8	
	3618T>C*	CRP	MTND1	t1.9	
HD-5	3394T>C	CRP; SM in acute leukaemia; PM “unclear” in LHON/NIDDM/CPT deficiency	MTND1	t1.10	
	4216T>C	CRP; haplogrup marker JT	MTND1	t1.11	
	11719G>A	CRP; UnP in oral cancer	MTND4	t1.12	
	13708G>A	CRP; haplogroup marker J	MTND5	t1.13	
	14766C>T	CRP	MTCYB	t1.14	
	14798T>C	CRP	MTCYB	t1.15	
	CTR-1	7621T>C	CRP	MTCO2	t1.16
		8291A>G	Novel	MTNC7	t1.17
	CTR-2	3348A>G	CRP	MTND1	t1.18
		4172T>A	Novel	MTND1	t1.19
7566G>A*		Novel	MTTD (tRNA asp)	t1.20	
CTR-3	11719G>A	CRP; UnP in oral cancer	MTND4	t1.21	
	11938C>T	CRP	MTND4	t1.22	
	14766C>T	CRP	MTCYB	t1.23	
	3348A>G	CRP	MTND1	t1.24	
	4172T>A	Novel	MTND1	t1.25	
	7566G>A*	Novel	MTTD (tRNA asp)	t1.26	
	11719G>A	CRP; UnP in oral cancer	MTND4	t1.27	
11938C>T	CRP	MTND4	t1.28		
	14766C>T	CRP	MTCYB	t1.29	

Note: the nomenclature of genes is presented according to MITOMAP; CRP: coding region polymorphism; *heteroplasmy; SM: somatic mutation; PM: point mutation; UnP: unpublished polymorphism; LHON: Leber hereditary optic neuropathy; NIDDM: non-insulin dependent diabetes mellitus; CPT: carnitine palmitoyl transferase.




Fig. 2. Apoptotic and necrotic cell death induced by 3-NP (A, B, and E) or STS (C, D, and E) in HD and CTR cybrids. Cells cultured in glass coverslips were incubated with 3-NP (1, 10 mM) or STS (1, 10 nM) for 24 h or 15 h, respectively. At the end of the incubation the cells were incubated for 3 min with Hoechst 33342 plus propidium iodide and observed under fluorescence microscopy for nuclei morphology (200–300 cells per field and 3 fields per condition were counted). (E) shows a representative image of the cells. Data are the mean \pm S.E.M. of 3 independent experiments performed in duplicates. Statistical analysis was performed by two-way ANOVA, followed by Bonferroni post test. * $p < 0.05$, ** $p < 0.01$ when compared to CTR cybrids; # $p < 0.05$, ## $p < 0.01$ and ### $p < 0.001$ when compared to control (untreated) conditions.

B and E) or 1 and 10 nM STS (Figs. 2C–E) and compared with non-treated cells (control). A significant number of apoptotic cells displaying condensed and/or fragmented chromatin was observed in HD cybrids incubated with 1 mM 3-NP ($p < 0.05$) and 10 mM 3-NP ($p < 0.001$) when compared to untreated HD cybrids (Fig. 2A). In these conditions, CTR cybrids exhibited a significant increase in the number of apoptotic cells only when incubated in the presence of 10 mM 3-NP ($p < 0.01$) (Fig. 2A). For the higher 3-NP concentration tested a significant difference between HD and CTR cybrids was observed ($p < 0.01$), suggesting an increased susceptibility of HD cybrids to undergo an apoptotic mode of cell death upon exposure to 3-NP (Fig. 2A). Incubation of HD and CTR cybrids with 1 mM 3-NP did not significantly affect the number of necrotic cells, compared to untreated conditions (control) (Fig. 2B). Conversely, CTR cybrids exhibited morphological characteristics of necrosis following exposure to 10 mM 3-NP, which were significantly more evident than in HD cybrids ($p < 0.01$) (Fig. 2B). These results evidence a higher susceptibility of CTR cybrids to undergo a necrotic mode of cell death in response to 3-NP exposure. Analysis of LDH release confirmed these observations (Fig. 3A). A significant increase in LDH release was observed in both CTR and HD cybrids subjected to 10 mM 3-NP; however, CTR cybrids showed a preferential mode of necrotic cell death, as determined by a higher loss of plasma membrane integrity (Fig. 3A).

We also tested the effect of STS on apoptotic and necrotic nuclei morphology on both HD and CTR cybrids (Figs. 2C–E). Our results




Fig. 3. Effect of 3-NP (A) or STS (B) on LDH release in HD and CTR cybrids. Cells were incubated in the absence or in the presence of 3-NP (1, 10 mM) or STS (1, 10 nM) for 24 h or 15 h, respectively, and LDH was determined spectrophotometrically as described in the Material and Methods. Data are the mean \pm S.E.M. of 4–8 independent experiments performed in duplicates. Statistical analysis was performed by two-way ANOVA, followed by Bonferroni post test. ^{***} $p < 0.001$ when compared to HD cybrids and ^{###} $p < 0.001$ when compared to control (untreated) conditions.

show that 1 nM STS produced a small, but significant, increase in the number of HD cybrids undergoing apoptosis, compared with CTR cybrids ($p < 0.05$) (Fig. 2C). This effect was more pronounced in the presence of 10 nM STS, since both CTR ($p < 0.01$) and HD cybrids ($p < 0.001$) showed a higher number of apoptotic nuclei compared to untreated cybrids (control) (Figs. 2C and E). Under these conditions, HD cybrids were more susceptible to apoptosis induced by 10 nM STS compared to CTR cybrids ($p < 0.01$). In cells exposed to 10 nM STS, we also observed a small increase in the number of necrotic cells, when compared to untreated conditions (control) ($p < 0.05$), but no differences were observed between HD and CTR cybrids (Fig. 2D). However, no significant differences caused by STS (1 or 10 nM) were observed on LDH release in both CTR and HD cybrids (Fig. 3B).

These results show that HD cybrids exhibit morphological characteristics of apoptosis following 3-NP or STS treatment, being the HD cybrids more susceptible to apoptosis compared with CTR cybrids. Conversely, upon 3-NP exposure, CTR cybrids appear to preferentially undergo a necrotic mode of cell death, whereas incubation with STS does not differentially affect necrotic cell death in HD and CTR cybrids.

Effect of 3-NP and STS on reactive oxygen species production

To explain the higher susceptibility of HD cybrids when exposed to toxic stimuli, we examined the production of endogenous reactive oxygen species (ROS). For this purpose, HD or CTR cybrids were incubated in the absence or presence of 3-NP or STS and the levels of superoxide ions and hydroperoxides were analyzed by measuring ethidium or DCF fluorescence, respectively.

Our results show no differences on superoxide levels between HD and CTR cybrids under basal conditions (untreated HD vs. CTR cybrids) (Fig. 4A). However, superoxide production increased in HD cybrids upon exposure to 3-NP (0.1–10 mM), compared with untreated conditions (control) (Fig. 4B). A significant difference in superoxide production in HD compared to CTR cybrids was only observed for the higher concentration of 3-NP tested (10 mM) ($p < 0.05$). Incubation with STS (0.1–10 nM) caused a significant increase in superoxide production in HD cybrids, as compared to CTR or untreated cybrids. Similarly to 3-NP, exposure to STS did not affect the levels of superoxide in CTR cybrids (Fig. 4C).

By measuring DCF fluorescence we demonstrate that under basal conditions HD cybrids are endowed with a significant higher amount of hydroperoxides production, compared to CTR cybrids ($p < 0.01$) (Fig. 4D); however, no differences between HD and CTR cybrids were observed when the cells were subjected to increasing concentrations of 3-NP (Fig. 4E). Incubation with 10 mM 3-NP increased hydroperoxides production, in HD and CTR cybrids, compared to untreated conditions (control) ($p < 0.001$) (Fig. 4E). Incubation with STS produced a dose-dependent increase in hydroperoxides production in HD cybrids compared to untreated conditions (control) and CTR cybrids (Fig. 4F), suggesting that HD cybrids are more susceptible to STS-induced hydroperoxide production. A significant increase in hydroperoxide production in CTR cybrids was only observed in the presence of the highest concentration of STS tested (10 nM) ($p < 0.01$).

Effect of 3-NP and STS on caspase-3 activation

Since HD cybrids exhibited a higher percentage of cells displaying apoptotic morphology (as determined in Fig. 2), we also investigated the effect of 3-NP and STS on caspase-3 activation in both CTR and HD cybrids (Figs. 5A and B). Although no significant changes were observed in CTR cybrids subjected to mitochondrial inhibition, treatment with 10 mM 3-NP was effective in inducing caspase-3-like activity in HD cybrids, when compared to untreated cybrids (control) ($p < 0.001$) or with CTR cybrids ($p < 0.01$) (Fig. 5A). STS incubation also caused a significant increase in caspase-3 activity in




Fig. 4. ROS production in HD and CTR cybrids. Cells were incubated in the absence or in the presence of 3-NP (0.1, 1 and 10 mM) or STS (0.1, 1 or 10 nM) for 24 h or 15 h, respectively. The relative levels of superoxide ions (A, B and C) were determined following ethidium fluorescence after a pre-incubation with 5 μ M DHE for 1 h, and the levels of hydroperoxides (D, E and F) were measured following DCF fluorescence after a 30 min incubation with 20 μ M DCFH₂-DA. Results are expressed as the mean \pm S.E.M. from 3 independent experiments. Statistical analysis was performed by two-way ANOVA, followed by Bonferroni post test. * p <0.05, ** p <0.01 and *** p <0.001 when compared to CTR cybrids and # p <0.05, ## p <0.01, ### p <0.001 when compared to control (untreated) conditions.

523 HD cybrids in the presence of the highest (10 nM) concentration of STS
 524 tested, when compared to control conditions (untreated HD cybrids)
 525 (p <0.01) (Fig. 5B). However, we did not observe significant differ-
 526 ences in the susceptibility of HD cybrids compared to CTR cybrids
 527 when examining caspase-3 activity in response to STS (Fig. 5B),
 528 despite the observation of a significant number of apoptotic nuclei in
 529 these conditions (Fig. 2C). These data were confirmed by α -spectrin
 530 cleavage into 150 and 120 kDa fragments, induced by 3-NP or STS
 531 exposure (data not shown).

532 *Effect of 3-NP on pro-apoptotic Cyt c, AIF, Bax, Bak, and Bim, and*
 533 *anti-apoptotic Bcl-2 protein levels*

534 Because cell death, including DNA fragmentation, caspase-3-like
 535 activation and superoxide production were more evident in HD

536 cybrids exposed to 3-NP, we characterized in more detail the levels of
 537 pro- and anti-apoptotic proteins involved in 3-NP-induced apoptosis
 538 in this model. The levels of both mitochondrial and cytosolic
 539 cytochrome c, Bax and Bcl-2 and mitochondrial Bak, Bim and AIF
 540 were analyzed by western blotting in HD and CTR cybrids (Fig. 6).
 541 Cytochrome c was released in a significant manner from mitochondria
 542 of HD cybrids subjected to 10 mM 3-NP, when compared to both
 543 untreated HD cybrids (control) (p <0.05) or CTR cybrids (p <0.01)
 544 (Fig. 6A). Interestingly, when statistical analysis was performed by
 545 unpaired Student's t test in control conditions, a significant increase in
 546 cytochrome c in cytosol of HD vs. CTR cybrids was also detected
 547 (p <0.05). Slight changes in cytochrome c release under basal
 548 conditions seem to correlate with a small decrease in mitochondrial
 549 membrane potential. AIF, which induces apoptotic cell death through
 550 a caspase-independent pathway, was released in a similar manner




Fig. 5. Caspase-3 activation induced by 3-NP (A) or STS (B) in HD and CTR cybrids. Cells were incubated in the absence or in the presence of 3-NP (1 and 10 mM) or STS (1 or 10 nM) for 24 h and 15 h, respectively. Caspase-3-like activity was measured by following the cleavage of the colorimetric substrate Ac-DEVD-pNA. The activity is expressed as the increase in optical density values above the control (untreated cybrids). Results are expressed as the mean \pm S.E.M. from 10–12 independent experiments performed in duplicates. Statistical analysis was performed by two-way ANOVA, followed by Bonferroni post test. ** $p < 0.01$ when compared to CTR cybrids; ## $p < 0.01$, ### $p < 0.001$ when compared to control (untreated) conditions.

from HD and CTR cybrids mitochondria upon exposure to 3-NP (Fig. 6B). The pro-apoptotic protein Bim was present in higher amounts in mitochondria derived from non-treated (control) HD, compared to CTR, cybrids ($p < 0.01$ analyzed by *t* test), but exposure to 3-NP did not highly affect Bim expression in HD cybrids (Fig. 6C). Interestingly, for the highest concentration of 3-NP tested (10 mM), CTR cybrids showed a significant increase in Bim levels in the mitochondria when compared to untreated conditions (control) ($p < 0.05$) or with HD cybrids exposed to 3-NP ($p < 0.001$) (Fig. 6C). Incubation with 3-NP did not significantly affect the levels of the proapoptotic protein Bak in mitochondria from both HD and CTR cybrids. However, our results demonstrate that under basal conditions (untreated cybrids) the levels of Bak are higher in HD than in CTR cybrids ($p < 0.05$) (Fig. 6D). Treatment with 3-NP (1 and 10 mM) increased the translocation of Bax from the cytosol to the mitochondria in both CTR and HD cybrids ($p < 0.05$); however, no significant differences were observed between HD and CTR cybrids (Fig. 6E). Finally, cytosolic or mitochondrial levels of the anti-apoptotic protein Bcl-2 were unaffected under basal or 3-NP-treated conditions in both HD and CTR cybrids (Fig. 6F).

Discussion

Mitochondria are central in the process of apoptosis, a mechanism leading to neuronal loss in neurodegenerative disorders like HD (Kroemer and Reed, 2000; Beal, 2005; García-Martínez et al., 2007; Yang et al., 2008). In the present study we provide evidence that

human HD cybrids show subtle mitochondrial modifications. Indeed, HD cybrids are more susceptible than CTR cybrids to mitochondrial-dependent cell degeneration produced by the mitochondrial complex II inhibitor 3-NP and the classic apoptotic inducer STS. In HD cybrids, treatment with 3-NP caused the release of mitochondrial cytochrome c, the subsequent activation of caspase-3, as well as the release of mitochondrial AIF. This effect appears to be mediated by mitochondrial translocation of Bax. Moreover, increased mitochondrial levels of Bim and Bak, a slight decrease in mitochondrial membrane potential concomitant with the release of cytochrome c, and increased hydroperoxide production in non-treated HD cybrids may explain the increased susceptibility to apoptosis caused by exposure to stress inducers (3-NP or STS). Conversely, CTR cybrids are more vulnerable to necrotic cell death upon 3-NP treatment, and no changes in caspase-3 activation are observed. Increased mitochondrial Bax, and particularly Bim, may contribute to promote a different mode of cell death in 3-NP treated-CTR cybrids.

Previous evidence showed that both nuclear and mitochondrial genomes are damaged in the 3-NP chemically induced HD mouse model and in the HD R6/2 transgenic mice (Acevedo-Torres et al., 2009). Lymphocytes from HD patients have higher frequencies of mtDNA deletions and oxidative stress, suggesting that CAG repeat instability, and thus mutant huntingtin, are a causative factor in mtDNA damage (Banoei et al., 2007). Moreover, decreased mtDNA content was correlated with the length of CAG repeats in leukocytes from HD patients (Liu et al., 2008). Data presented in Table 1 suggest that the mtDNA sequence variations are not causal for HD in the patients included in the present study, since some are also found in CTR cybrids. Additionally, there is no information regarding the CAG repeat genotype in the HD gene of CTR subjects, and thus we cannot exclude that they may be carriers for the intermediate or expanded allele and that they may develop any type of neurodegenerative disease later in life, including dementia. The presence of mtDNA variations, including an 8656A > G variant in one patient, was recently shown in a screening study for mutations in the *tRNA(Leu/Lys)* and *MTATP6* genes of 20 patients with HD (Kasraie et al., 2008). However, the nucleotides 8915–9207 of the same gene do not present any sequence variation in our study. Table 1 also presents one HD cybrid line carrying the 3394T > C mutation with status “unclear,” previously described in cases suffering from Leber Hereditary Optic Neuropathy (LHON), which was shown to be related with HD features (Morimoto et al., 2004). Despite these observations, we cannot exclude that other genes outside the regions investigated may be involved in the disease or that mtDNA involvement is either related to deletion events or copy number alterations.

Unchanged mtDNA sequence variations correlate with the fact that no mitochondrial respiratory chain defects were found in HD, compared to CTR cybrids. These results are in agreement with previous data showing no substantial modifications in mitochondrial complexes activity in cybrid cell lines containing mtDNA from HD patients (Swerdlow et al., 1999). Furthermore, there were no significant changes in the activity of mitochondrial respiratory complexes (I–IV) or in superoxide formation among the six HD cybrid lines used in the current study. Thus, our data suggest that other mitochondrial modifications induced by full-length and/or fragments of mutant huntingtin, such as protein post-translational modifications, are retained in HD cybrids, which may be related with an interaction of mutant huntingtin with the organelle in HD carriers platelets. However, we could not detect huntingtin associated with the mitochondrial fractions derived from HD cybrids, as detected by western blotting using the anti-huntingtin antibody MAB2166 (Chemicon) (data not shown). Although HD cybrids do not express mutant huntingtin and thus cannot be directly compared with models expressing mutant huntingtin, in striatal cell lines expressing full-length mutant huntingtin (derived from knock-in mice) no significant effects on respiratory complexes activities were observed either (Milakovic and Johnson, 2005).

641 Mitochondrial dysfunction has been frequently associated with
 642 increased generation of ROS, promoting intracellular oxidative stress
 643 and leading to protein, lipid and DNA oxidation. Indeed, oxidative
 644 damage was shown to play an important role in the pathogenesis and
 645 progression of HD in the R6/2 transgenic mouse model (Perluigi et al.,
 646 2005) and also in post-mortem samples obtained from the striatum
 647 and cortex of human HD brain (Sorolla et al., 2008). Our data also
 648 demonstrate that, under basal conditions, HD cybrids are endowed
 649 with a significant higher production of hydroperoxides when
 650 compared to CTR cybrids. These data differ from a previous study
 651 showing no evidence of ROS generation, as measured with DCFH₂-DA
 652 in untreated HD cybrids (Swerdlow et al., 1999); however, these
 653 authors did not exclude a subtle mitochondrial pathology in these
 654 cells. In agreement, we show that HD cybrids are more vulnerable
 655 than CTR cybrids to produce superoxide upon 3-NP or STS treatment,
 656 whereas increased hydroperoxide production was mainly evoked by
 657 STS, suggesting that the presence of higher amounts of hydroper-

658 oxides in untreated HD cybrids masks the effect caused by 3-NP-
 659 induced mitochondrial inhibition.

660 The mitochondrial toxin 3-NP was shown to cause energy
 661 deficiency and cell death by necrosis and apoptosis in striatal, cortical
 662 and hippocampal cells (Behrens et al., 1995; Pang and Geddes, 1997;
 663 Almeida et al., 2004, 2006; Ruan et al., 2004; Brouillet et al., 2005), and
 664 both processes of cell damage have been proven to involve
 665 mitochondria (Kroemer and Reed, 2000). In the present work,
 666 exposure of HD cybrid cell lines to 3-NP or STS caused DNA
 667 fragmentation and moderate caspase-3 activation, evidencing an
 668 increased susceptibility of HD cybrids to apoptosis. However, 3-NP
 669 treated CTR cybrids died predominantly by necrosis, not involving
 670 caspase-3 activation. Recent data obtained in our laboratory using the
 671 same cybrid lines also showed that endogenous levels of ATP are
 672 higher in HD cybrids compared to CTR cybrids (author's unpublished
 673 data). Preserved ATP levels in HD cybrids may explain the preferential
 674 mode of cell death by apoptosis.








Fig. 6. Changes in cytosolic and mitochondrial levels of cytochrome c, AIF, Bax, Bim, Bak, and Bcl-2 in HD and CTR cybrids. Cells were incubated in the absence or in the presence of 3-NP (1 and 10 mM) for 24 h. Cytosolic and mitochondrial fractions were obtained as described in the Material and Methods and cytochrome c (A), AIF (B), Bim (C), Bak (D), Bax (E), and Bcl-2 (F) protein levels were analyzed by Western blotting. α -Tubulin or Cox1 were used as loading controls for analysis of cytosolic or mitochondrial fractions, respectively. The results are expressed as the mean \pm S.E.M. from 3–10 independent experiments. Statistical analysis was performed by two-way ANOVA, followed by Bonferroni post test. ** p < 0.01 and *** p < 0.001 when compared to CTR cybrids; # p < 0.05, ## p < 0.01 when compared to control (untreated) conditions. § p < 0.05 and §§ p < 0.01 when the HD cybrids were compared with CTR cybrids under control (untreated) conditions, and statistical analysis was performed by using Student's t test.

C. Bim



D. Bak



675 Mutant huntingtin interaction with the mitochondria, as previ-
 676 ously observed in neuronal mitochondrial membranes of YAC72
 677 transgenic mice (Panov et al., 2002), may cause mitochondrial
 678 abnormalities leading to cytochrome c release, and a decrease in
 679 mitochondrial membrane potential. These authors also observed that
 680 defects in mitochondrial calcium handling in HD brain mitochondria
 681 may underlie HD pathology. Similar effects were observed by us in
 682 YAC128 HD striatal neurons upon excitotoxic stimuli (Oliveira et al.,
 683 2006). However data presented by Swerdlow et al., 1999, showed no
 684 differences in CCCP-evoked cytosolic calcium between HD and CTR
 685 cybrids, suggesting equivalent mitochondrial calcium handling.

686 We have recently reported that 3-NP causes mitochondrial-
 687 dependent apoptotic neuronal death through the release of cytochrome
 688 c and consequent activation of caspases, or the release of AIF in cortical
 689 neurons (Almeida et al., 2004, 2006, 2009). Our present data
 690 demonstrate an increase in cytochrome c and AIF release from
 691 mitochondria, the translocation of the pro-apoptotic protein Bax to
 692 mitochondria, but no changes on the levels of Bak or the anti-apoptotic
 693 protein Bcl-2 in HD cybrids exposed to 3-NP. These data appear to be
 694 consistent with possible subtle effects of mutant huntingtin in the
 695 mitochondria of HD cybrids. Indeed, mutant huntingtin fragments were
 696 previously shown to directly induce the opening of the mitochondrial
 697 permeability transition pore in isolated mouse liver mitochondria, with
 698 the consequent release of cytochrome c (Choo et al., 2004) which leads
 699 to caspase cascade activation. Myoblasts obtained from presymptomatic
 700 and symptomatic HD subjects also show mitochondrial depolarization,
 701 cytochrome c release and increased activities of caspases 3, 8 and 9
 702 (Ciammola et al., 2006). Increased Bax expression in B and T
 703 lymphocytes, and monocytes from HD patients, but no alterations in
 704 Bcl-2 expression levels were also recently observed by us in blood
 705 samples from HD patients (Almeida et al., 2008). Moreover, it was
 706 recently shown that Bax and Bak can mediate apoptosis without
 707 discernable association with the putative BH3-only activators (Bim, Bid

and Puma) (Willis et al., 2007). Interestingly, and consistently with
 moderate sustained modifications of mitochondrial function in HD
 cybrids, non-treated HD cells showed moderate levels of cytosolic
 cytochrome c and increased mitochondrial levels of both Bim and Bak.
 It was previously shown that cell death induction by Bim(S) can occur
 independently of anti-apoptotic Bcl-2 protein binding, but requires Bim
 (S) mitochondrial targeting (Weber et al., 2007). In the R6/1 mouse
 model of HD, increased levels of Bim and Bid were observed at later
 stages of the disease (García-Martínez et al., 2007). Moreover,
 constitutive expression of the transgene Tet/HD94 mice resulted in
 increased levels of Bim and Bid proteins, but only the Bid protein
 returned to wild-type levels 5 months after mutant huntingtin
 shutdown (García-Martínez et al., 2007).

Our results suggest that mtDNA sequence variation is not a primary
 contributor to the development of HD pathology. Thus we hypothesize
 that HD cybrids may retain abnormal mitochondria from the symp-
 tomatic HD patient platelets. Indeed, both caspase-dependent and
 independent cell damage occurs in HD cybrids in response to 3-NP
 exposure, reflecting subtle modifications in mitochondria from HD
 patients. These alterations are considerably less than those observed in
 cybrid lines obtained from sporadic forms of Parkinson's (Esteves et al.,
 2008) and Alzheimer's (Cardoso et al., 2004) disease. Nevertheless, this
ex vivo human mitochondrial HD model appears to be useful for
 studying mitochondrial-dependent defects and elucidate cell death
 mechanisms induced by toxic stimuli in a sub-population of HD patients.
 Moreover, the HD cybrids may be valuable for testing pharmacological
 compounds associated with improved mitochondrial function.

Acknowledgments

The authors thank the patients and families who generously
 contributed to this study. We also thank Dr. Isabel Nunes (Center for
 Neuroscience and Cell Biology, University of Coimbra) for expert




Fig. 6 (continued).

739 technical assistance with cell culture maintenance, and Dr. Russell H.
 740 Swerdlow (University of Virginia, Charlottesville, VA, USA) for the gift of ρ^0 NT2 cells. This work was supported by Project III/BIO/49/2005
 741 (Instituto de Investigação Interdisciplinar, III, Universidade de
 742 Coimbra, Portugal), Project STARTER S-09 (Gabinete de Apoio à
 743 Investigação, GAI, Faculdade de Medicina, Universidade de Coimbra)
 744 and Project POCI/SAU-NEU/57310/2004 (Fundação para a Ciência e a
 745 Tecnologia, Portugal).
 746

747 References

- 748 Acevedo-Torres, K., Berríos, L., Rosario, N., Dufault, V., Skatchkov, S., Eaton, M.J., Torres-
 749 Ramos, C.A., Ayala-Torres, S., 2009. Mitochondrial DNA damage is a hallmark of
 750 chemically induced and the R6/2 transgenic model of Huntington's disease. *DNA*
 751 *Repair* 8, 126–136.
 752 Almeida, S., Domingues, A., Rodrigues, L., Oliveira, C.R., Rego, A.C., 2004. FK506 prevents
 753 mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in
 754 rat primary cortical cultures. *Neurobiol. Dis.* 17, 435–444.
 755 Almeida, S., Brett, A.C., Góis, I.N., Oliveira, C.R., Rego, A.C., 2006. Caspase-dependent and
 756 -independent cell death induced by 3-nitropropionic acid in rat cortical neurons. *J.*
 757 *Cell Biochem.* 98, 93–101.
 758 Almeida, S., Sarmiento-Ribeiro, A.B., Januário, C., Rego, A.C., Oliveira, C.R., 2008. Evidence
 759 of apoptosis and mitochondrial abnormalities in peripheral blood cells of
 760 Huntington's disease patients. *Biochem. Biophys. Res. Commun.* 374, 599–603.

- Almeida, S., Laço, M., Cunha-Oliveira, T., Oliveira, C.R., Rego, A.C., 2009. BDNF regulates
 761 BIM expression levels in 3-nitropropionic acid-treated cortical neurons. *Neurobiol.*
 762 *Dis.* 35, 448–456.
 763 Aronin, N., Chase, K., Young, C., Sapp, E., Schwarz, C., Matta, N., Kornreich, R.,
 764 Landwehrmeyer, B., Bird, E., Beal, M.F., Vonsattel, J.P., Smith, T., Carraway, R., Boyce,
 765 F.M., Young, A.B., Penney, J.B., DiFiglia, M., 1995. CAG expansion affects the expression
 766 of mutant huntingtin in the Huntington's disease brain. *Neuron* 15, 1193–1201.
 767 Banoei, M.M., Houshmand, M., Panahi, M.S.S., Shariati, P., Rostami, M., 2007.
 768 Huntington's disease and mitochondrial DNA deletions: Event or regular
 769 mechanism for mutant huntingtin protein and CAG repeats expansion?! *Cell*
 770 *Mol. Neurobiol.* 27, 867–875.
 771 Beal, M.F., 2005. Mitochondria take center stage in aging and neurodegeneration. *Ann.*
 772 *Neurol.* 58, 495–505.
 773 Behrens, M.I., Koh, J., Canzoniero, L.M., Sensi, S.L., Csernansky, C.A., Choi, D.W., 1995. 3-
 774 Nitropropionic acid induces apoptosis in cultured striatal and cortical neurons.
 775 *Neuroreport* 6, 545–548.
 776 Bergmeyer, H.U., Bernt, E., 1974. UV-assay with pyruvate and NADH. *Methods of*
 777 *enzymatic analysis.* Academic press, New York, pp. 574–579.
 778 Bezprozvanny, I., Hayden, M.R., 2004. Deranged neuronal calcium signaling and
 779 Huntington disease. *Biochem. Biophys. Res. Commun.* 322, 1310–1317.
 780 Bossy-Wetzell, E., Petrilli, A., Knott, A.B., 2008. Mutant huntingtin and mitochondrial
 781 dysfunction. *Trends Neurosci.* 31, 609–616.
 782 Brouillet, E., Guyot, M.C., Mittoux, V., Altairac, S., Condé, F., Palfi, S., Hantraye, P., 1998.
 783 Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is
 784 sufficient to initiate striatal degeneration in rat. *J. Neurochem.* 70, 794–804.
 785 Brouillet, E., Jacquard, C., Bizat, N., Blum, D., 2005. 3-Nitropropionic acid: a
 786 mitochondrial toxin to uncover physiopathological mechanisms underlying striatal
 787 degeneration in Huntington's disease. *J. Neurochem.* 95, 1521–1540.
 788

- 789 Cardoso, S.M., Santana, I., Swerdlow, R.H., Oliveira, C.R., 2004. Mitochondria dysfunction
790 of Alzheimer's disease cybrids enhances Abeta toxicity. *J. Neurochem.* 89,
791 1417–1426.
- 792 Carré, M., André, N., Carles, G., Borghi, H., Brichese, L., Briand, C., Braguer, D., 2002.
793 Tubulin is an inherent component of mitochondrial membranes that interacts with
794 the voltage-dependent anion channel. *J. Biol. Chem.* 277, 33664–33679.
- 795 Choo, Y.S., Johnson, G.V., MacDonald, M., Detloff, P.J., Lesort, M., 2004. Mutant huntingtin
796 directly increases susceptibility of mitochondria to the calcium-induced perme-
797 ability transition and cytochrome c release. *Hum. Mol. Genet.* 13, 1407–1420.
- 798 Ciammola, A., Sassone, J., Alberti, L., Meola, G., Mancinelli, E., Russo, M.A., Squitieri, F.,
799 Silani, V., 2006. Increased apoptosis, Huntingtin inclusions and altered differenti-
800 ation in muscle cell cultures from Huntington's disease subjects. *Cell Death Differ.*
801 13, 2068–2078.
- 802 del Hoyo, P., García-Redondo, A., de Bustos, F., Molina, J.A., Sayed, Y., Alonso-Navarro, H.,
803 Caballero, L., Arenas, J., Jiménez-Jiménez, F.J., 2006. Oxidative stress in skin
804 fibroblasts cultures of patients with Huntington's disease. *Neurochem. Res.* 31,
805 1103–1109.
- 806 Esteves, A.R., Domingues, A.F., Ferreira, I.L., Januário, C., Swerdlow, R.H., Oliveira, C.R.,
807 Cardoso, S.M., 2008. Mitochondrial function in Parkinson's disease cybrids
808 containing an nt2 neuron-like nuclear background. *Mitochondrion* 8, 219–228.
- 809 Fan, M.M.Y., Raymond, L.A., 2007. N-methyl-D-aspartate (NMDA) receptor function and
810 excitotoxicity in Huntington's disease. *Prog. Neurobiol.* 81, 272–293.
- 811 García-Martínez, J.M., Pérez-Navarro, E., Xifré, X., Canals, J.M., Díaz-Hernández, M.,
812 Trioulier, Y., Brouillet, E., Lucas, J.J., Alberch, J., 2007. BH3-only proteins Bid and Bim
813 (EL) are differentially involved in neuronal dysfunction in mouse models of
814 Huntington's disease. *J. Neurosci. Res.* 85, 2756–2769.
- 815 Gil, J.M., Rego, A.C., 2008. Mechanisms of neurodegeneration in Huntington's disease.
816 *Eur. J. Neurosci.* 27, 2803–2820.
- 817 Grazina, M., Pratas, J., Silva, F., Oliveira, S., Santana, I., Oliveira, C., 2006. Genetic basis of
818 Alzheimer's dementia: role of mtDNA mutations. *Genes Brain Behav.* 5 (S2), 92–107.
- 819 Huntington Study Group, 1996. Unified Huntington's Disease Rating Scale: reliability
820 and consistency. *Mov. Disord.* 11, 136–142.
- 821 Kasraie, S., Houshmand, M., Banoei, M.M., Ahari, S.E., Panahi, M.S., Shariati, P., Bahar, M.,
822 Moin, M., 2008. Investigation of tRNA(Leu/Lys) and ATPase 6 Genes Mutations in
823 Huntington's Disease. *Cell. Mol. Neurobiol.* 28, 933–938.
- 824 Kuhn, A., Goldstein, D.R., Hodges, A., Strand, A.D., Sengstag, T., Kooperberg, C., Becanovic,
825 K., Pouladi, M.A., Sathasivam, K., Cha, J.H., Hannan, A.J., Hayden, M.R., Leavitt, B.R.,
826 Dunnett, S.B., Ferrante, R.J., Albin, R., Shelbourne, P., Delorenzi, M., Augood, S.J., Faull,
827 R.L., Olson, J.M., Bates, G.P., Jones, L., Luthi-Carter, R., 2007. Mutant huntingtin's
828 effects on striatal gene expression in mice recapitulate changes observed in human
829 Huntington's disease brain and do not differ with mutant huntingtin length or wild-
830 type huntingtin dosage. *Hum. Mol. Genet.* 16, 1845–1861.
- 831 Kroemer, G., Reed, J.C., 2000. Mitochondrial control of cell death. *Nat. Med.* 6, 513–519.
- 832 Liu, C.S., Cheng, W.L., Kuo, S.J., Li, J.Y., Soong, B.W., Wei, Y.H., 2008. Depletion of
833 mitochondrial DNA in leukocytes of patients with poly-Q diseases. *J. Neurol. Sci.*
834 264, 18–21.
- 835 Mancuso, M., Orsucci, D., Siciliano, G., Murri, L., 2008. Mitochondria, mitochondrial DNA
836 and Alzheimer's disease. What comes first? *Curr. Alzheimer Res.* 5, 457–468.
- 837 Milakovic, T., Johnson, G.V.W., 2005. Mitochondrial respiration and ATP production are
838 significantly impaired in striatal cells expressing mutant huntingtin. *J. Biol. Chem.*
839 280, 30773–30782.
- 840 Morimoto, N., Nagano, I., Deguchi, K., Murakami, T., Fushimi, S., Shoji, M., Abe, K., 2004.
841 Leber hereditary optic neuropathy with chorea and dementia resembling
842 Huntington disease. *Neurology* 63, 2451–2552.
- 843 Oliveira, J.M., Chen, S., Almeida, S., Riley, R., Goncalves, J., Oliveira, C.R., Hayden, M.R.,
844 Nicholls, D.G., Ellerby, L.M., Rego, A.C., 2006. Mitochondrial-dependent Ca²⁺
845 handling in Huntington's disease striatal cells: effect of histone deacetylase
846 inhibitors. *J. Neurosci.* 26, 11174–11186.
- 847 Onyango, I., Khan, S., Miller, B., Swerdlow, R., Trimmer, P., Bennett Jr., P., 2006. 847
848 Mitochondrial genomic contribution to mitochondrial dysfunction in Alzheimer's
849 disease. *J. Alzheimers Dis.* 9, 183–193.
- 850 Pang, Z., Geddes, J.W., 1997. Mechanisms of cell death induced by the mitochondrial
851 toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis. *J.*
852 *Neurosci.* 17, 3064–3073.
- 853 Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J.,
854 Greenamyre, J.T., 2002. Early mitochondrial calcium defects in Huntington's disease
855 are a direct effect of polyglutamines. *Nat. Neurosci.* 5, 731–736.
- 856 Perluigi, M., Poon, H.F., Maragos, W., Pierce, W.M., Klein, J.B., Calabrese, V., Cini, C., De
857 Marco, C., Butterfield, D.A., 2005. Proteomic analysis of protein expression and
858 oxidative modification in r6/2 transgenic mice: a model of Huntington disease.
859 *Mol. Cell Proteomics* 4, 1849–1861.
- 860 Rego, A.C., de Almeida, L.P., 2005. Molecular targets and therapeutic strategies in
861 Huntington's disease. *Curr. Drug Targets* 4, 361–381.
- 862 Ruan, Q., Lesort, M., MacDonald, M.E., Johnson, G.V., 2004. Striatal cells from mutant
863 huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II
864 inhibitor-induced cell death through a non-apoptotic pathway. *Hum. Mol. Genet.*
865 13, 669–681.
- 866 Sas, K., Robotka, H., Toldi, J., Vécsei, L., 2007. Mitochondria, metabolic disturbances,
867 oxidative stress and kynurenine system, with focus on neurodegenerative
868 disorders. *J. Neurol. Sci.* 257, 221–239.
- 869 Sawa, A., Wiegand, G.W., Cooper, J., Margolis, R.L., Sharp, A.H., Lawler, J.F.Jr,
870 Greenamyre, J.T., Snyder, S.H., Ross, C.A., 1999. Increased apoptosis of Huntington
871 disease lymphoblasts associated with repeat length-dependent mitochondrial
872 depolarization. *Nat. Med.* 10, 1194–1198.
- 873 Schapira, A.H., 1998. Mitochondrial dysfunction in neurodegenerative disorders.
874 *Biochim. Biophys. Acta* 1366, 225–233.
- 875 Sorolla, M.A., Reverter-Branchat, G., Tamarit, J., Ferrer, I., Ros, J., Cabiscol, E., 2008.
876 Proteomic and oxidative stress analysis in human brain samples of Huntington
877 disease. *Free Radic. Biol. Med.* 45, 667–678.
- 878 Swerdlow, R.H., Parks, J.K., Cassarino, D.S., Shilling, A.T., Bennett Jr., J.P., Harrison, M.B.,
879 Parker Jr., W.D., 1999. Characterization of hybrid cell lines containing mtDNA from
880 Huntington's disease patients. *Biochem. Biophys. Res. Commun.* 291, 701–704.
- 881 Tabrizi, S.J., Cleeter, M.W., Xuereb, J., Taanman, J.W., Cooper, J.M., Schapira, A.H., 1999.
882 Biochemical abnormalities and excitotoxicity in Huntington's disease brain. *Ann.*
883 *Neurol.* 45, 25–32.
- 884 Trottier, Y., Devys, D., Imbert, G., Saudou, F., An, I., Lutz, Y., Weber, C., Agid, Y., Hirsch, E.
885 C., Mandel, J.L., 1995. Cellular localization of the Huntington's disease protein and
886 discrimination of the normal and mutated form. *Nat. Genet.* 10, 104–110.
- 887 Turner, C., Cooper, J.M., Schapira, A.H., 2007. Clinical correlates of mitochondrial
888 function in Huntington's disease muscle. *Mov. Disord.* 22, 1715–1721.
- 889 Vanlangenakker, N., Berghe, T.V., Krysko, D.V., Festjens, N., Vandenabeele, P., 2008.
890 Molecular mechanisms and pathophysiology of necrotic cell death. *Curr. Mol. Med.*
891 8, 207–220.
- 892 Ward, M.W., Rego, A.C., Frenguelli, B.G., Nicholls, D.G., 2000. Mitochondrial membrane
893 potential and glutamate excitotoxicity in cultured cerebellar granule cells. *J.*
894 *Neurosci.* 20, 7208–7219.
- 895 Weber, A., Paschen, S.A., Heger, K., Wilfling, F., Frankenberg, T., Bauerschmitt, H.,
896 Seiffert, B.M., Kirschnek, S., Wagner, H., Häcker, G., 2007. BimS-induced apoptosis
897 requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2
898 proteins. *J. Cell Biol.* 177, 625–636.
- 899 Willis, S.N., Fletcher, J.L., Kaufmann, T., van Delft, M.F., Chen, L., Czabotar, P.E., Ierino, H.,
900 Lee, E.F., Fairlie, W.D., Bouillet, P., Strasser, A., Kluck, R.M., Adams, J.M., Huang, D.C.,
901 2007. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not
902 Bax or Bak. *Science* 315, 856–859.
- 903 Yang, J.-L., Weissman, L., Bohr, V., Mattson, M.P., 2008. Mitochondrial DNA damage and
904 repair in neurodegenerative disorders. *DNA Repair* 7, 1110–1120.